Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
- 28 June 2008
- Vol. 56, 7-11
- https://doi.org/10.1111/j.1398-9995.2001.00002.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonistJournal of Allergy and Clinical Immunology, 1998
- Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced BronchoconstrictionNew England Journal of Medicine, 1998
- Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsThorax, 1997
- Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD 4) receptor antagonist, in patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1996
- Leukotriene E4 and granulocytic infiltration into asthmatic airwaysThe Lancet, 1993
- SRS‐A leukotrienes decrease the activity of human respiratory ciliaClinical and Experimental Allergy, 1987
- Vascular Effects of Leukotriene D4 in Human SkinJournal of Investigative Dermatology, 1987
- Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humansClinical and Experimental Allergy, 1986
- Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma.BMJ, 1985
- Leukotriene- and Histamine-Induced Increases in Vascular Permeability and Interstitial Transport in the SkinJournal of Investigative Dermatology, 1985